{"id":"W4411628399","doi":"10.1016/j.esmoop.2025.105332","title":"70O Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): Secondary endpoints","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lanthanide and Transition Metal Complexes","field":"Materials Science","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Daiichi Sankyo Europe; Defence and Security Accelerator; Takeda Oncology; Genentech; BeiGene; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; European Commission; Seagen; AstraZeneca; Novocure; Regeneron Pharmaceuticals; Amgen; Deciphera Pharmaceuticals; Sociedad Española de Oncología Médica; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Mersana Therapeutics; Myriad Genetics; Bristol-Myers Squibb; American Society of Clinical Oncology; Vifor Pharma","keywords":"Nab-paclitaxel; Paclitaxel; Medicine; Ovarian cancer; Internal medicine; Oncology; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001124471,0.001192163,0.001302697,0.0004476445,0.0002894389,0.0008750399,0.0006978611,0.001118882,0.004264999],"category_scores_gemma":[0.0006317592,0.000361644,0.001471022,0.0003326284,0.0005676846,0.0003919783,0.000232302,0.00256553,0.0009356404],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000946424,"about_ca_system_score_gemma":0.001051711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002179213,"about_ca_topic_score_gemma":0.005165748,"domain_scores_codex":[0.9996709,0.0001504518,0.00001625741,0.00004477281,0.00003427318,0.0000833849],"domain_scores_gemma":[0.9995054,0.00008274912,0.00009356302,0.00003749385,0.00003389717,0.0002469731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7395732,0.05294954,0.003809095,0.001184856,0.002434567,0.0002233901,0.0001887864,0.003175575,0.07084359,0.0004248188,0.008295545,0.1168971],"study_design_scores_gemma":[0.4531794,0.5083005,0.0135097,0.00008363403,0.001425658,0.0003571226,0.00007191164,0.001319644,0.01361045,0.0002934733,0.007799342,0.00004917074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811466,0.005178546,0.0007295034,0.000709174,0.0002500547,0.002870808,0.003672053,0.0002015145,0.005241816],"genre_scores_gemma":[0.9741822,0.004440347,0.002090615,0.001231858,0.0002846156,0.002732888,0.006828504,0.0001079343,0.00810096],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004264999,"threshold_uncertainty_score":0.01426786,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02590728600350213,"score_gpt":0.324439035187439,"score_spread":0.2985317491839369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}